Skip to main content
    T

    Transcode Therapeutics Inc (RNAZ)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.40
    +0.05 (+3.70%)

    Market Cap: $22.35M

    Last updated: Nov 17, 2026 at 4:15 PM ET

    Transcode Therapeutics Inc (RNAZ) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Transcode Therapeutics (RNAZ) has a market cap of $22.35M and an enterprise value of $20.82M. Its share count is up 1275.49% from a year earlier.

    Total Valuation

    Enterprise value is 6.83% below the market cap, as cash exceeds debt.

    Market Cap$22.35M
    Enterprise Value$20.82M
    Latest price (Nov 17, 2026)$1.40

    Key Dates

    Last Earnings DateAug 14, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 1098.01% in the quarter ended Sep 30, 2026.

    Shares Outstanding11.47M
    Shares Change (YoY)+1275.49%
    Shares Change (QoQ)+1098.01%

    Price Statistics

    The stock is down 84.85% over 52 weeks and trades 14.63% below its 50-day average.

    Beta (1Y)0.76
    52-Week Change-84.85%
    1-Month Change-17.65%
    3-Month Change-56.39%
    6-Month Change-77.34%
    5-Year Change-100.00%
    Total Return (1Y)-84.85%
    Total Return (3Y CAGR)-94.75%
    Total Return (5Y CAGR)-94.13%
    Return vs SPY (1Y)-96.06%
    Max Drawdown (1Y)-89.30%
    Max Drawdown (3Y)-99.99%
    Sharpe Ratio (1Y)-1.96
    Correlation with SPY (1Y)0.11
    50-Day Average$1.64
    200-Day Average$5.64
    52-Week Range$1.29 to $12.60
    RSI (14 Days)38.2
    Average Volume (20 Days)23.81K

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 0.96x current liabilities, and total debt is 0.10x shareholder equity.

    Current Ratio0.96x
    Quick Ratio0.96x
    Debt / Equity0.10x

    Returns and Efficiency

    Return on invested capital is -412.71% and return on equity is -452.25% over the last 12 months.

    Return on Equity (ROE)-452.25%
    Return on Assets (ROA)-324.83%
    Return on Invested Capital (ROIC)-412.71%

    Scores

    RNAZ has a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.

    Piotroski F-Score3 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue was $0 over the last 12 months.

    Revenue$0
    Operating Income-$150.26M
    Pretax Income-$145.23M
    Net Income-$145.36M
    Reported EPS (TTM)-$50.68

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 71.82% of the $44.75M in total assets.

    Cash and Equivalents$4.64M
    Total Debt$3.11M
    Net Cash$1.53M
    Net Cash Per Share$0.13
    Working Capital-$284.40K
    Shareholder Equity$32.14M
    Book Value Per Share$2.80
    Tangible Book Value-$5.90M
    Total Assets$44.75M
    Total Liabilities$12.61M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    Operating Cash Flow-$26.18M
    FCF Per Share-$1.55
    Depreciation and Amortization$114.47K

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Dividends and Yields

    RNAZ does not pay a dividend.

    Buyback Yield0.00%
    Shareholder Yield0.00%

    Stock Splits

    The last split was a 1-for-28 reverse split on May 15, 2025.

    Last Split DateMay 15, 2025
    Split TypeReverse split
    Split Ratio1:28

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About RNAZ

    What is RNAZ's market cap?

    Transcode Therapeutics has a market cap of $22.35M. Its enterprise value, which adds debt and subtracts cash, is $20.82M.

    How many shares of RNAZ are outstanding?

    Transcode Therapeutics has 11.47M shares outstanding. The count is up 1275.49% from a year earlier.

    Does RNAZ pay a dividend?

    No. Transcode Therapeutics does not pay a dividend.

    How much debt does RNAZ have?

    Transcode Therapeutics has $3.11M of total debt and $4.64M of cash and equivalents, a net cash position of $1.53M.